Dittami, James P.
University of Massachusetts Medical Center
University of Massachusetts Medical School
In the last year, an estimated 36.7 million people were living with the Human Immunodeficiency Virus (HIV), with 5,700 new infections occurring daily. Currently, there are 26 FDA approved antiretroviral drugs for the treatment of HIV; however, drug resistance still remains a major problem associated with the current treatments. GS-8374 is a novel protease inhibitor that makes use of a diethyl phosphonate group at the P1 position and has a superior resistance profile when compared to that of current FDA approved inhibitors. For this project three new analogues of GS-8374 were synthesized and tested against the I84V mutant, which confers resistance to most protease inhibitors, of HIV protease.
Worcester Polytechnic Institute
Major Qualifying Project
All authors have granted to WPI a nonexclusive royalty-free license to distribute copies of the work, subject to other agreements. Copyright is held by the author or authors, with all rights reserved, unless otherwise noted.
Chemistry and Biochemistry